Further, the use of these protease inhibitors can lead to metabolic disturbances such as hyperglycemia, hyperlipidemia and lipodystrophy, which may also contribute to adverse cardiovascular outcomes (Hill, Sawyer, & Gazzard, 2009; Tsiodras, Mantzoros, Hammer, & Samore, 2000).